NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

Executive Summary

• NurExone Biologic Inc. has been accepted into the BioFab Startup Lab, part of ARMI’s BioFabUSA program, a federally‑supported initiative to accelerate biomanufacturing scale‑up.
• Participation gives NurExone access to GMP‑grade facilities, mentorship, and resources that could speed development of its exosome platform and support plans for a U.S. GMP‑compliant production facility (Exo‑Top Inc.).
• The company views the program as a strategic catalyst to enhance value for shareholders and attract strategic partners.

Key Details

• Program Acceptance: NurExone is now part of ARMI’s BioFab Startup Lab, a six‑month accelerator providing early‑stage biotech firms with access to manufacturing infrastructure, mentorship, and biomanufacturing expertise.
• Federal Support: The program is funded through a grant from the U.S. Economic Development Administration and aligns with recent White House bioeconomy initiatives.
• Strategic Benefit: CEO Dr. Lior Shaltiel states the program will help NurExone advance GMP‑grade naive exosome production, shorten time‑to‑market for its therapies, and improve the company’s value proposition to partners and shareholders.
• Facility Plans: Exo‑Top Inc., NurExone’s U.S. subsidiary, is advancing plans to establish a dedicated GMP‑compliant facility for large‑scale exosome manufacturing.
• Potential Commercial Impact: Access to ARMI resources may enable faster scale‑up of the company’s lead product ExoPTEN and other exosome‑based therapies targeting CNS injuries, supporting entry into multi‑billion‑dollar markets.
• Forward‑Looking Statements: The release includes typical risk disclosures regarding early‑stage development, financing needs, regulatory approvals, and execution of the GMP facility plan.

Notable Quotes

“Biofabrication is becoming the industrial foundation of next‑generation medicine. Federal support for programs like this reflects how U.S. priorities are expanding beyond semiconductors and clean energy toward biomanufacturing.” – Dr. Lior Shaltiel, CEO